Lunora

Menu

Women’s Menstrual Health & Period Cramp Relief Solutions in India

Menstrual health is a critical yet often overlooked aspect of women’s overall well-being in India. Millions of women experience monthly discomfort, particularly period cramps (dysmenorrhea), which significantly affects their daily activities, productivity, and quality of life. Despite its prevalence, menstrual health remains surrounded by stigma, limited awareness, and inadequate access to safe and effective solutions.

Prevalence of Period Pain (Dysmenorrhea) in India

Severity of Period Pain (India Data)

Official Study:

  • 34.2% Severe pain
  • 36.6% Moderate pain
  • 29.2% Mild pain (PMC)

Lunora+ Research & Development Study

Heat-Assisted Diclofenac Transdermal Patch for Menstrual Pain Management

Lunora+ is an advanced heat-assisted transdermal therapeutic system designed to address primary dysmenorrhea (menstrual pain) through a dual-action approach:

  • Controlled therapeutic heat (~40–42°C)
  • Localized delivery of diclofenac (NSAID)

Diclofenac is a clinically established analgesic for menstrual pain, with strong evidence ranking it among the most effective OTC options. However, conventional oral administration is associated with gastrointestinal side effects, while standard topical systems suffer from limited skin permeation.

Lunora+ introduces a scientifically engineered solution that leverages controlled heat to enhance drug diffusion across the skin. Based on diffusion principles and clinical thermotherapy evidence, heat can increase transdermal drug flux by ~2×, significantly improving local drug delivery.

This project integrates drug delivery science, thermal engineering, and women-centric design, aiming to create a non-invasive, wearable, and scalable therapeutic platform.

Clinical Need & Problem Statement

Primary dysmenorrhea affects a significant proportion of women globally and is characterized by:

  • Elevated prostaglandin levels
  • Uterine hypercontractility
  • Reduced uterine blood flow

Limitations of Current Therapies

  • Oral NSAIDs (e.g., diclofenac): Effective but associated with gastrointestinal risks
  • Heat therapy: Clinically beneficial but lacks portability and sustained delivery

Unmet Need

A solution that is:

  • Portable and discreet
  • Continuous and long-lasting
  • Combining comfort with therapeutic efficacy

Scientific Rationale

Role of Diclofenac

Diclofenac acts by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis—the key driver of menstrual cramps. Clinical analyses rank diclofenac among the top-performing NSAIDs for dysmenorrhea management.

Transdermal Delivery Advantage

  • Localized drug action
  • Reduced systemic exposure
  • Avoidance of gastrointestinal side effects

However, standard transdermal systems show limited permeability, with flux typically in the range of 1–5 µg/cm²·h, necessitating enhancement strategies.

Role of Heat Therapy

Controlled heat (~40°C):

  • Promotes vasodilation
  • Relaxes uterine muscles
  • Modulates pain signals

Clinical evidence suggests that continuous low-level heat can provide pain relief comparable to NSAIDs in certain cases.

Heat-Assisted Drug Delivery

Based on Fick’s Law of Diffusion, drug flux increases with temperature due to:

  • Higher diffusion coefficient
  • Increased skin permeability
  • Enhanced local blood circulation

Studies indicate that increasing skin temperature from 32°C to ~42°C can double drug flux, forming the core scientific foundation of Lunora+.

Formulation & Material Engineering

Multi-Layer Patch Architecture

The patch consists of:

  • Breathable outer backing layer
  • Oxygen-control membrane
  • Heat-generating core (iron-based system)
  • Thermal distribution layer
  • Drug-in-adhesive matrix
  • Skin-contact adhesive layer
  • Release liner

Technology Overview: Dual-Action Patch

Lunora+ integrates two synergistic systems:

Controlled Heat System

  • Temperature: 40–42°C
  • Duration: 6–8 hours
  • Mechanism: Iron oxidation reaction with oxygen-controlled membrane

Drug Delivery System

  • Diclofenac embedded in a drug-in-adhesive polymer matrix
  • Enhanced with penetration enhancers (e.g., oleic acid, propylene glycol)
  • Designed for sustained and localized release

This structure ensures:

  • Controlled heat delivery
  • Uniform temperature distribution
  • Stable and sustained drug release

Penetration Enhancement Strategy

To overcome low baseline permeability, Lunora+ incorporates chemical enhancers, including:

  • Oleic acid (OA): Lipid disruption for increased permeability
  • Isopropyl myristate (IPM): Enhances lipid fluidity
  • Propylene glycol (PG): Improves drug solubility and hydration
  • Menthol: Dual role as enhancer and mild analgesic

These enhancers work synergistically with heat to significantly improve transdermal flux and drug bioavailability.

Safety Considerations

Thermal Safety

  • Target temperature: ~40°C
  • Upper safety limit: ≤42°C
  • Oxygen-controlled design prevents overheating

Drug Safety

  • Expected systemic exposure significantly lower than oral diclofenac
  • Reduced gastrointestinal risk

Skin Compatibility

  • Use of hypoallergenic medical-grade adhesives
  • Planned irritation and sensitization testing
Scroll to Top